MSH2 and ovarian cancer: We previously reported a case series of double carriers of LS and hereditary breast and ovarian cancer pathogenic variants, suggesting that double MSH2/MSH6 and BRCA1/BRCA2 carriage is not associated with early disease onset or a more severe phenotype [23].